Here's How Much Investing $1,000 In Berkshire Hathaway Stock In 2010 Would Be Worth Today

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY) total return for the decade was 250.5%. But there's no question some big-name stocks did much better than others along the way.Berkshire's Difficult Decade: One underperformer of the last decade was Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B).Berkshire struggled throughout the past decade to keep pace with a bull market that was led by high-growth, high-valuation tech stocks. Buffett is one of the most iconic value investors of all time, but value stocks have underperformed in a climate of historically low interest rates and skyrocketing corporate debt.One of Buffett's best moves of the past 10 years was his decision to go all-in on Apple, Inc (NASDAQ: AAPL) in May 2016. At the time, Apple shares were trading at around $110 per share. Roughly five years later, Apple is now trading at $444 and it's by far Berkshire's largest holding, worth around $111.5 billion.But Buffett also had plenty of missteps in the past decade as well. Buffett invested in airline stocks in 2016 only to sell them all in early 2020 near the market bottom during the COVID-19 sell-off.Berkshire's Class B shares started the 2010s trading at around $70 after a 50-to-1 stock split in early 2010. Berkshire hit its decade low of $65.35 in late 2011. Berkshire shares then began a steady march higher over the next three years, peaking at $152.94 in late 2014.From there, Berkshire spent most of the next two years trading sideways in a wide range of between $125 and $150. The stock finally broke out to the upside in late 2016.2020 And Beyond: Berkshire ultimately peaked at $231.61 in early 2020, its high point of the last 10 years. However, Berkshire shares were hammered in early 2020 during the broad market COVID-19 sell-off, and the stock dropped to as low as $159.50, its lowest point since 2017. While the stock has since rebounded to around $210, it has still delivered underwhelming overall performance over the past 10 years.In fact, $1,000 worth of Berkshire stock in 2010 would be worth about $2,614 today, assuming reinvested dividends.Looking ahead, analysts expect Berkshire's climb to resume in the coming months. The average price target among the three analysts covering the stock is $223.45, suggesting 6.7% upside from current levels.President Barack Obama meets with Warren Buffett in the Oval Office in 2011. Official White House Photo by Pete Souza.See more from Benzinga * Why Warren Buffett May Have Changed His Tune On Berkshire Buybacks * Exclusive: Genius Brands CEO Sees Profitability 'By The End Of The Year'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

• 
  Buffett buys back $5.1B in Berkshire stock

  Yahoo Finance Video
• 
  Warren Buffett Signals Big Shift In Investing Stance As Berkshire Reports

  Investor's Business Daily

Gold Price Forecast – September Correction Targets

The near-term trends in precious metals reached extremes – a temporary top is becoming likely. A daily close below $2000 in gold would confirm a spike-high top and beginning of a 1 to 2-month correction.

Here’s what Trump’s payroll tax deferral could mean for your paycheck

The president’s executive order deferred, but didn’t forgive, an employee’s Social Security tax liabilities.

• 
  Trucking Companies Caught In Trump's Payroll Tax Deferment Order

  Benzinga
• 
  Social Security could be vulnerable under President Trump’s plan for payroll taxes

  MarketWatch

Vaxart’s (VXRT) Stock Will Surge 130% From Current Levels, Says Analyst

Vaccine specialist Vaxart (VXRT) reported 2Q20 earnings last week, but since its vaccine candidates are all in development, the results themselves were of little importance. More pertinent for investors were updates on the pipeline’s progress. Specifically, Vaxart’s COVID-19 oral vaccine candidate.As the only oral vaccine to be selected for inclusion in the government’s Operation Warp Speed (OWS) program, Vaxart’s offering has shown promise in pre-clinical trials, with a Phase 1 study expected to begin sometime in 2H20.While Vaxart’s incredible rise this year (shares are up by over 2,500%) has been solely COVID-driven, the company has other vaccines in development. These include its H1N1 influenza oral tablet vaccine, which recently progressed through a BARDA-funded Phase 2 challenge study evaluating its efficacy against Sanofi's Fluzone. This study yielded positive results.Additionally, Vaxart has established a working relationship with vaccine leader Janssen, who will make use of Vaxart’s proprietaryVAAST platform and its R&D skills to develop immunogenic oral vaccines.With several other manufacturing and scale up collaborations in place (Emergent BioSolutions, Kindred Bio, and Attwil Medical Solutions) and a cash position of $140 million, B.Riley FBR analyst Mayank Mamtani argues Vaxart is set to capitalize on its newly elevated position. In addition to keeping an eye on the COVID-19 vaccine candidate’s progress, the 5-star analyst looks ahead to results from the Janssen collaboration and tells investors to take advantage of the recent market fluctuations.Mamtani said, “We expect these data to provide incremental validation for the proprietary VAAST platform and VXRT's R&D capability to produce immunogenic oral vaccines, targeted specifically to the lung mucosa. The recent pullback in shares, ~45%-plus off its 52-week high, despite an impressive stock move year-to-date, i.e., 2500%, is unwarranted, in our view, given our core thesis of VXRT being well positioned to emerge as one of the key players in the second wave of vaccines.”Mamtani, therefore, reiterated a Buy rating and has a $22 price target on the shares. What does this mean for investors? Upside potential of a whopping 130%. (To watch Mamtani’s track record, click here)Only one other analyst has been tracking Vaxart’s progress over the past three months. The additional Buy rating bestows on Vaxart a Moderate Buy consensus rating. With an average price target of $14.50, there’s room for a 54% uptick in the coming months. (See Vaxart stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.